Ocumension to stage HK IPO July 10



Ocumension Therapeutics (1477) announced plans to hold an initial public offering (IPO) of 105,930,000 shares at HKD 13.94 to 15.53 (USD 1.80 to 2.00) per share, for a total of HKD 1.39 billion to HKD 1.55 billion (USD 180 million to 200 million). The IPO is sponsored by Morgan Stanley and Goldman Sachs, and is up for grabs July 10.

Ocumension is an ophthalmology medicine platform incubated by 6 Dimensions Capital in January 2017, with 16 assets covering major anterior and posterior eye diseases. Lead product candidate Yutiq (OT-401) is an innovative intravitreal implant designed to treat chronic non-infectious uveitis involving the posterior segment of the eye, and chronic NIU-PS, an indication lacking standard treatment in China, with sustained release of corticosteroid active ingredients through a single 36-month administration. The product has the green light for Phase III clinical trials in China, and is the first and only 36-month fluocinolone release uveitis therapy approved in the US. The company is building an ophthalmic drugs plant in Suzhou, expected to churn out 455 million doses a year. China’s ophthalmic drug market is estimated to increase from RMB 19.4 billion (USD 2.7 billion) in 2019, to RMB 40.8 billion (USD 5.8 billion) in 2024, citing Frost & Sullivan statistics.

Ocumension is yet to turn a profit, posting RMB 1.33 billion (USD 187 million) in net losses in 2019. The IPO proceeds will go mostly towards research and development of core product OT401 and other drug candidates, acquisition of manufacturing facilities in Suzhou, and working capital.

Reference:
IPO

Related news
U.S.-based ophthalmic drug developer EyePoint Pharmaceuticals Inc., (Nasdaq:EYPT) signed a licensing deal with China-based Ocumension Therapeutics, handing over exclusive development and commercialization rights in the Greater China territory to the Durasert technology, used to treat chronic, non-infectious posterior segment uveitis, an inflammatory disease that is among the leading causes of blindness globally.
Brazil has incorporated 17 new drugs into the National List of Essential Medicines (Relação Nacional de Medicamentos Essenciais; Rename) during 2017.
Spain-based Laboratorios Salvat, S.A. and Lee’s Pharmaceutical (HK) Ltd, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Ltd (HK: 0950), jointly announced the signing of an exclusive license and supply agreement for the marketing and distribution of Duoxal (ciprofloxacin + fluocinolone acetonide) ear drops for the territory of Greater China, including Hong Kong, Macau and Taiwan, as well as the option to add Thailand.
Recent news
According to GBI analysis, Colombia’s National Food and Drug Surveillance Institute (INVIMA) recently approved Pfizer subsidiary Wyeth’s antihemorrhagic BeneFIX (recombinant coagulation factor IX), Pfizer’s human growth hormone analog Somavert (pegvisomant), and Mundipharma’s antineoplastic Difolta (pralatrexate).
Argentina’s Ministry of Health (MoH) this week launched two drug procurement processes.
Mexico’s Congress last week passed an Industrial Innovation Protection Law, which was announced last month.
Paraguay's Ministry of Health (MSPBS) this week launched its Drugs and Medical Supplies National Monitoring System, an online platform that keeps track of health products distribution in the public healthcare system as well as their cost.
Germany-based giant Merck KGaA has opened its M Lab Collaboration Center in Pudong, at the heart of the biomedical sciences and research community in Shanghai.
The cloud summit of World Artificial Intelligence Conference (WAIC) held in Shanghai this year saw China’s technology giant Tencent launch iDrug, its first AI-empowered drug research and development (R&D) platform, designed to galvanize novel drug development via technology. iDrug covers the whole process of pre-clinical development: protein structure screening, virtual screening, molecular design and optimization, and synthetic route planning.
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a clinical study for its donafenib combined with Genor Biopharma Co., Ltd’s programmed death-1 (PD-1) inhibitor genolimzumab in advanced hepatocellular carcinoma (HCC), gastric cancer including gastroesophageal junction adenocarcinoma (GC/GEJ), renal cell carcinoma (RCC), colorectal cancer (CRC), and other advanced solid tumors. Donafenib (CM4307) is a small-molecule oral multi-kinase inhibitor with activity against serine-threonine kinase (Raf/MEK/ERK) signaling, vascular endothelial growth factor receptor (VEGFRs) and platelet-derived growth factor receptor (PDGFR), designed to directly and indirectly inhibit tumor cell proliferation and growth.
Analytics Snapshot


Analytics Snapshot